Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung cancer.
October 9, 2015
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
October 2, 2015
The approval of a combination of two immunotherapy drugs for melanoma represents a treatment milestone.
October 1, 2015